Q-omics provides the consensus-scored ZCWPW2 profile across patient tissues and cancer cell-line models. ZCWPW2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZCWPW2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, ZCWPW2 RNA expression shows 20,564 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where ZCWPW2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZCWPW2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZCWPW2 survival associations across molecular data types. ZCWPW2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZCWPW2 RNA expression–survival associations across cancer types. High ZCWPW2 expression shows unfavorable associations in KICH and SCLC, but favorable associations in KIRC, LUAD, LAML and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZCWPW2 RNA expression.
This table summarizes ZCWPW2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZCWPW2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZCWPW2 shows lower tumor expression in KIRC, THCA, HNSC, KICH, LUAD and LUSC. The KIRC box plot shows higher ZCWPW2 RNA expression in normal versus tumor tissue (log2 FC = −0.533, t-test p < 0.001).
This table shows molecular features associated with ZCWPW2 in patient tissues and cancer cell lines. In patient samples, ZCWPW2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZCWPW2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
